GW Pharmaceuticals PLC (NASDAQ:GWPH) Rating Reiterated by Leerink Swann

GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Swann in a research note issued to investors on Thursday. They presently have a $160.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $162.00. Leerink Swann’s price objective would suggest a potential upside of 57.25% from the stock’s current price. Leerink Swann also issued estimates for GW Pharmaceuticals PLC’s Q4 2017 earnings at ($2.12) EPS, FY2017 earnings at ($6.36) EPS and FY2018 earnings at ($6.96) EPS.

Other research analysts have also recently issued reports about the stock. Maxim Group set a $135.00 price target on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday, August 7th. ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Zacks Investment Research cut shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Monday, May 15th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $147.94.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 101.75 on Thursday. The company has a 50 day moving average of $107.48 and a 200-day moving average of $113.40. The firm’s market cap is $2.58 billion. GW Pharmaceuticals PLC has a 12-month low of $79.62 and a 12-month high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period last year, the business earned ($0.05) earnings per share. Analysts predict that GW Pharmaceuticals PLC will post ($5.28) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/gw-pharmaceuticals-plc-nasdaqgwph-rating-reiterated-by-leerink-swann.html.

Hedge funds have recently made changes to their positions in the stock. Creative Planning raised its position in GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,603 shares during the last quarter. Bank of Montreal Can raised its position in GW Pharmaceuticals PLC by 2,419.0% in the first quarter. Bank of Montreal Can now owns 2,519 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 2,419 shares during the last quarter. Rothschild Investment Corp IL raised its position in GW Pharmaceuticals PLC by 2.7% in the first quarter. Rothschild Investment Corp IL now owns 10,437 shares of the biopharmaceutical company’s stock worth $1,262,000 after buying an additional 272 shares during the last quarter. Candriam Luxembourg S.C.A. raised its position in GW Pharmaceuticals PLC by 21.4% in the first quarter. Candriam Luxembourg S.C.A. now owns 17,000 shares of the biopharmaceutical company’s stock worth $2,056,000 after buying an additional 3,000 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in GW Pharmaceuticals PLC during the first quarter worth $520,000. Institutional investors own 75.77% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply